State Street’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10M | Sell |
5,961,175
-160,541
| -3% | -$233K | ﹤0.01% | 2701 |
|
|
2026
Q1 | $8.08M | Buy |
6,121,716
+209,493
| +4% | +$375K | ﹤0.01% | 2725 |
|
|
2025
Q4 | $11.1M | Buy |
5,912,223
+2,579
| +0% | +$4.96K | ﹤0.01% | 2598 |
|
|
2025
Q3 | $7.56M | Buy |
5,909,644
+155,061
| +3% | +$210K | ﹤0.01% | 2790 |
|
|
2025
Q2 | $7.14M | Sell |
5,754,583
-625,009
| -10% | -$722K | ﹤0.01% | 2788 |
|
|
2025
Q1 | $7.53M | Sell |
6,379,592
-47,383
| -0.7% | -$72.7K | ﹤0.01% | 2696 |
|
|
2024
Q4 | $11.8M | Buy |
6,426,975
+150,819
| +2% | +$294K | ﹤0.01% | 2535 |
|
|
2024
Q3 | $10.7M | Buy |
6,276,156
+340,766
| +6% | +$560K | ﹤0.01% | 2560 |
|
|
2024
Q2 | $8.13M | Buy |
5,935,390
+166,503
| +3% | +$336K | ﹤0.01% | 2684 |
|
|
2024
Q1 | $21.6M | Buy |
5,768,887
+144,558
| +3% | +$846K | ﹤0.01% | 2160 |
|
|
2023
Q4 | $55.2M | Buy |
5,624,329
+252,447
| +5% | +$2.06M | ﹤0.01% | 1654 |
|
|
2023
Q3 | $44.9M | Buy |
5,371,882
+43,231
| +0.8% | +$494K | ﹤0.01% | 1696 |
|
|
2023
Q2 | $70.9M | Sell |
5,328,651
-34,168
| -0.6% | -$415K | ﹤0.01% | 1451 |
|
|
2023
Q1 | $62.1M | Buy |
5,362,819
+135,323
| +3% | +$1.35M | ﹤0.01% | 1500 |
|
|
2022
Q4 | $42.8M | Buy |
5,227,496
+176,143
| +3% | +$1.52M | ﹤0.01% | 1745 |
|
|
2022
Q3 | $29.3M | Buy |
5,051,353
+710,784
| +16% | +$4.08M | ﹤0.01% | 1953 |
|
|
2022
Q2 | $19.2M | Sell |
4,340,569
-88,396
| -2% | -$537K | ﹤0.01% | 2280 |
|
|
2022
Q1 | $40.3M | Buy |
4,428,965
+271,315
| +7% | +$3.12M | ﹤0.01% | 1897 |
|
|
2021
Q4 | $85.1M | Sell |
4,157,650
-112,957
| -3% | -$2.73M | ﹤0.01% | 1431 |
|
|
2021
Q3 | $109M | Buy |
4,270,607
+17,032
| +0.4% | +$505K | 0.01% | 1187 |
|
|
2021
Q2 | $149M | Buy |
4,253,575
+222,602
| +6% | +$6.47M | 0.01% | 1026 |
|
|
2021
Q1 | $134M | Buy |
4,030,973
+6,283
| +0.2% | +$220K | 0.01% | 1015 |
|
|
2020
Q4 | $104M | Sell |
4,024,690
-308,296
| -7% | -$5.24M | 0.01% | 1117 |
|
|
2020
Q3 | $42.8M | Buy |
4,332,986
+91,157
| +2% | +$525K | ﹤0.01% | 1575 |
|
|
2020
Q2 | $14.6M | Buy |
4,241,829
+659,610
| +18% | +$2.25M | ﹤0.01% | 2204 |
|
|
2020
Q1 | $11M | Buy |
3,582,219
+340,259
| +10% | +$1.39M | ﹤0.01% | 2230 |
|
|
2019
Q4 | $16.7M | Buy |
3,241,960
+259,950
| +9% | +$1.32M | ﹤0.01% | 2266 |
|
|
2019
Q3 | $15.4M | Buy |
2,982,010
+72,788
| +3% | +$407K | ﹤0.01% | 2224 |
|
|
2019
Q2 | $17.6M | Buy |
2,909,222
+150,186
| +5% | +$1.05M | ﹤0.01% | 2199 |
|
|
2019
Q1 | $19.9M | Buy |
2,759,036
+156,705
| +6% | +$1.13M | ﹤0.01% | 2041 |
|
|
2018
Q4 | $19.3M | Buy |
2,602,331
+219,621
| +9% | +$1.39M | ﹤0.01% | 2004 |
|
|
2018
Q3 | $12.9M | Buy |
2,382,710
+135,369
| +6% | +$581K | ﹤0.01% | 2440 |
|
|
2018
Q2 | $7.98M | Buy |
2,247,341
+354,804
| +19% | +$984K | ﹤0.01% | 2644 |
|
|
2018
Q1 | $3.88M | Buy |
1,892,537
+84,603
| +5% | +$220K | ﹤0.01% | 2915 |
|
|
2017
Q4 | $4.77M | Buy |
1,807,934
+169,788
| +10% | +$594K | ﹤0.01% | 2816 |
|
|
2017
Q3 | $8.6M | Buy |
1,638,146
+116,901
| +8% | +$502K | ﹤0.01% | 2513 |
|
|
2017
Q2 | $5.42M | Buy |
1,521,245
+106,607
| +8% | +$430K | ﹤0.01% | 2693 |
|
|
2017
Q1 | $7.32M | Buy |
1,414,638
+28,504
| +2% | +$140K | ﹤0.01% | 2518 |
|
|
2016
Q4 | $5.27M | Buy |
1,386,134
+68,226
| +5% | +$496K | ﹤0.01% | 2668 |
|
|
2016
Q3 | $11.8M | Sell |
1,317,908
-681
| -0.1% | -$5.69K | ﹤0.01% | 2097 |
|
|
2016
Q2 | $9.28M | Buy |
1,318,589
+245,925
| +23% | +$2.25M | ﹤0.01% | 2267 |
|
|
2016
Q1 | $9.12M | Buy |
1,072,664
+135,746
| +14% | +$1.34M | ﹤0.01% | 2229 |
|
|
2015
Q4 | $12.3M | Buy |
936,918
+115,597
| +14% | +$1.04M | ﹤0.01% | 2069 |
|
|
2015
Q3 | $3.01M | Buy |
821,321
+16,504
| +2% | +$80.7K | ﹤0.01% | 2801 |
|
|
2015
Q2 | $4.64M | Buy |
804,817
+807
| +0.1% | +$4.67K | ﹤0.01% | 2658 |
|
|
2015
Q1 | $4.69M | Buy |
804,010
+28,941
| +4% | +$200K | ﹤0.01% | 2589 |
|
|
2014
Q4 | $6.08M | Sell |
775,069
-9,610
| -1% | -$61.5K | ﹤0.01% | 2474 |
|
|
2014
Q3 | $3.85M | Buy |
784,679
+62,213
| +9% | +$325K | ﹤0.01% | 2676 |
|
|
2014
Q2 | $4.46M | Buy |
722,466
+41,661
| +6% | +$209K | ﹤0.01% | 2658 |
|
|
2014
Q1 | $3.65M | Buy |
680,805
+45,260
| +7% | +$286K | ﹤0.01% | 2757 |
|
|
2013
Q4 | $3.33M | Buy |
635,545
+89,710
| +16% | +$412K | ﹤0.01% | 2810 |
|
|
2013
Q3 | $3.02M | Buy |
545,835
+5,546
| +1% | +$19.3K | ﹤0.01% | 2832 |
|
|
2013
Q2 | $1.36M | Buy |
+540,289
| New | +$1.35M | ﹤0.01% | 3123 |
|
Other funds holding PACB
AIM
NAMA
State Street's PACB Position: Q2 2026 in Review
State Street reduced its Pacific Biosciences (PACB) stake by 2.6% in Q2 2026, selling an estimated $233K and leaving 5,961,175 shares worth $10M. The position accounts for ﹤0.01% of the portfolio, ranked #2701.
State Street first reported a position in PACB in Q2 2013 and has held it in 53 quarters since. The position peaked at $149M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- State Street held 5,961,175 shares of Pacific Biosciences worth $10M as of Q2 2026.
- State Street sold 160,541 Pacific Biosciences shares in Q2 2026, an estimated $233K.
- Pacific Biosciences made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2701 holding.
- State Street first reported a position in Pacific Biosciences in Q2 2013 and has held it in 53 quarters since.
- State Street's Pacific Biosciences position peaked at $149M in Q2 2021.
- 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.